Mistletoe plant extract in patients with nonmuscle invasive bladder cancer: Results of a phase Ib/IIa single group dose escalation study

Bibliographic Information
Authors: Rose A.; El-Leithy T.; Dorp F.V.; Zakaria A.; Eisenhardt A.; Tschirdewahn S.; Rübben H.
Journal: Journal of Urology
Publisher: Elsevier Inc.
Publication Date: October 2015
Volume / Issue: Volume 194 / Issue 4
Pages: 939–943
ISSN: 225347
DOI: 10.1016/j.juro.2015.04.073
Scopus: View on Scopus
PubMed: 25910967
Document Type: Article
Authors and Affiliations
Rose A., Department of Urology, HELIOS Marien Klinik, Wanheimerstr. 167a, Duisburg, 47053, Germany; El-Leithy T., Theodor Bilharz Research Institute, Cairo, Egypt; Dorp F.V., Department of Urology, HELIOS Marien Klinik, Wanheimerstr. 167a, Duisburg, 47053, Germany; Zakaria A., Theodor Bilharz Research Institute, Cairo, Egypt; Eisenhardt A., Praxis Urologie Rhein/Ruhr, Mülheim an der Ruhr, Germany; Tschirdewahn S., Department of Urology, University Hospital of Essen, Essen, Germany; Rübben H., Department of Urology, University Hospital of Essen, Essen, Germany
Abstract
Purpose We determined the maximum tolerated dose, safety and effectiveness of intravesical instillation of mistletoe extract after transurethral resection of nonmuscle invasive bladder cancer. Materials and Methods In this single group dose escalation study patients with nonmuscle invasive bladder cancer were treated with weekly instillations of mistletoe extract for 6 weeks. Four weeks before instillation therapy all patients underwent transurethral resection of bladder tumors. During this procedure a marker tumor was left. At 12 weeks after the start of instillation therapy transurethral resection of the marker tumor or biopsy of the former marker tumor location was done so that patients were tumor free when entering followup until week 48. During the followup clinical assessment laboratory tests for safety and cystoscopy were done every 12 weeks. Results A total of 36 patients were treated with increasing doses of mistletoe extract. We found no dose limiting toxicity up to a dose of 675 mg of plant extract. Besides local reactions we saw hints that pyrexia may develop. All adverse events were well manageable. At 12 weeks a marker tumor remission rate of 55.6% (95% CI 38.1 to 72.1) was achieved. At 1 year a recurrence rate of 26.3% (95% CI 9.1 to 51.2) was observed. Conclusions In this study intravesical instillation of mistletoe extract as treatment in patients with nonmuscle invasive bladder cancer was shown to be safe and well tolerated. Promising data on efficacy were observed and will be further investigated in a phase III study. © 2015 American Urological Association Education and Research, Inc.
Keywords
abnoba viscum; administration; intravesical; mistletoe; treatment outcome; urinary bladder neoplasms; Administration, Intravesical; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Phytotherapy; Plant Extracts; hemoglobin variant; Viscum album extract; plant extract; adult; Article; bladder biopsy; clinical article; clinical assessment; controlled study; cystoscopy; drug dose escalation; drug dose increase; drug safety; fever; follow up; hematuria; human; human tissue; laboratory test; leukocyturia; maximum tolerated dose; non muscle invasive bladder cancer; open study; phase 2 clinical trial; priority journal; proteinuria; recurrence risk; side effect; transurethral resection; tumor biopsy; tumor regression; urinary tract infection; clinical trial; intravesical drug administration; pathology; phase 1 clinical trial; tumor invasion
Citation Information
Scopus Citations: 17
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
